LATEST FROM IPOX^®

News

News and updates from IPOX^®, including media mentions, interviews, research and press releases.

Media mentions · Reuters

Reuters: IPOX^® Research Associate Lukas Muehlbauer Comments on PayPay's Nasdaq Debut

A recent Reuters article covers the highly anticipated $880 million Nasdaq IPO of SoftBank’s digital payment giant, PayPay. Despite global market volatility, the Japanese app successfully debuted with a $10.7 billion valuation. IPOX^® Research Associate Lukas Muehlbauer provided commentary on the offering's strategic pricing and the company's unique market position. Muehlbauer highlighted that we are currently in an IPO "buyers' market" and noted that PayPay's dominant domestic strength insulates it from broader geopolitical and macroeconomic concerns.

March 12, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Research Associate Lukas Muehlbauer Comments on MiniMed's Nasdaq Debut Amid Market Volatility

Reuters covered the Nasdaq debut of Medtronic's diabetes unit, MiniMed, which opened below its offer price amid heightened market volatility. The $5.35 billion listing highlights ongoing challenges in the new issues market. IPOX^® Research Associate Lukas Muehlbauer provided expert commentary on the debut, noting that while the offering "shows that the U.S. IPO market is still open," current economic conditions clearly dictate "that it has become a price-sensitive buyers' market."

March 6, 2026Lukas Muehlbauer

Media mentions · Bloomberg

Bloomberg: IPOX^® Associate Muehlbauer Comments on the Surge of European Defense IPOs

A recent Bloomberg article highlights the massive outperformance of European defense and aerospace IPOs, which have averaged 87% gains since 2020. Driven by geopolitical tensions and NATO rearmament, this surge in investor demand is prompting a fresh wave of public listings. IPOX^® Research Analyst Lukas Muehlbauer provided expert commentary, explaining that ongoing conflicts have created unprecedented backlogs, making IPOs a practical way for defense firms to raise cash and expand capacity.

March 5, 2026

Media mentions · Reuters

Reuters: IPOX^® CEO Josef Schuster Comments on PayPay's $13.4 Billion U.S. IPO

Reuters highlights SoftBank-backed PayPay’s upcoming $13.4 billion U.S. IPO, a highly anticipated offering expected to boost a volatile listing market. Discussing current market dynamics, IPOX^® CEO Josef Schuster noted robust investor appetite is particularly strong for specialty firms across healthcare and select fintech that are insulated from geopolitical and AI-related risks.

March 3, 2026Josef Schuster

Media mentions · Reuters

Reuters: IPOX^® Research Associate Lukas Muehlbauer Comments on MiniMed's $7.9 Billion IPO Valuation

A recent Reuters article highlights Medtronic’s plan to spin off its diabetes unit, MiniMed, targeting a $7.9 billion valuation in its upcoming U.S. IPO. Seeking to raise up to $784 million, the move allows Medtronic to focus on high-margin growth markets. IPOX^® Research Associate Lukas Muehlbauer provided expert commentary on the spin-off, noting that while MiniMed offers investors pure-play exposure to diabetes technology as an established business, its recent net losses mean investors will demand a clear path to profitability.

February 24, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Research Associate Muehlbauer Comments on Generate Biomedicines' IPO

Reuters highlights Generate Biomedicines' upcoming U.S. IPO, targeting a $2.17 billion valuation. As the biotech IPO market resurges, the firm aims to raise $425 million for its AI-driven drug discovery pipeline. IPOX^® Research Associate Lukas Muehlbauer provided expert commentary, noting that Generate's institutional backing and pharma partnerships offer significant credibility. However, he emphasized that investors will closely scrutinize the platform's valuation, demanding clear proof of its AI capabilities.

February 23, 2026

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu Comments on Clear Street’s Withdrawn IPO Amid Market Volatility

Reuters reports that Wall Street broker Clear Street has withdrawn its U.S. IPO amid market volatility and AI disruption fears. The withdrawal highlights ongoing challenges for fintech firms navigating weak sector sentiment. IPOX^® VP Kat Liu provided expert commentary, noting the risks of forcing a poorly received offering. "If demand wasn't there even at a severe discount, pushing through a weakly received deal would have risked the stigma of a 'failed' IPO," Liu explained

February 20, 2026Kat Liu

Media mentions · Bloomberg

Bloomberg: IPOX^® Associate Muehlbauer Comments on European IPOs and Follow-On Offerings

A recent Bloomberg article notes that while recent European stock debuts face market pressure, traditional sectors like banking and energy demonstrate strong resilience. Amid a slow market for follow-on offerings, IPOX^® Research Associate Lukas Muehlbauer commented on the challenges of underwater stocks.

February 20, 2026

Media mentions · Reuters

Reuters: IPOX^® Research Associate Muehlbauer Comments on Liftoff Mobile's Withdrawn IPO Plans

A recent Reuters article highlights Blackstone-backed Liftoff Mobile's decision to withdraw its U.S. IPO amid a sharp software sector selloff. This sudden delay reflects broader market volatility driven by rapid AI advancements threatening established economic moats. IPOX^® Research Associate Lukas Muehlbauer provided expert commentary on the situation, noting that private equity sponsors prefer withdrawing over accepting deeply disappointing valuations. Muehlbauer emphasized that current investor skepticism is a healthy sign of a disciplined market, preventing overheating and benefiting long-term pipeline stability.

February 17, 2026

News

Stay ahead of the next listing.